Skip to content

XORTX
  • About
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Coronavirus – COVID-19 Program
    • Autosomal Dominant Polycystic Kidney Disease
    • Diabetic Nephropathy
  • Strategic Partnerships
  • Investors
    • Press Releases
    • Presentations
    • Media
    • Independent Research
    • Financials
    • SEDAR
    • Transfer Agent
    • Upcoming Events
  • Contact
Site Search

Sample Page

Recent Press Releases

XORTX Confirms $1 Million in Warrant Exercise Proceeds

  • March 2, 2021
  • by Sean Ford

CALGARY, Alberta, March 02, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc.
(“XORTX” or the “Company”) (CSE: XRX;
OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative
therapies to treat progressive kidney disease, is pleased to announce that
4,286,438 warrants that were issued in connection with the February 2020
private placement and expired February 28, 2021 have been exercised for
aggregate proceeds of $1,037,524.
› Read more

Recent Press Releases

XORTX Confirms $1 Million in Warrant Exercise Proceeds

  • March 2, 2021
  • by aaronbb

CALGARY, Alberta, March 02, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that 4,286,438 warrants that were issued in connection with the February 2020 private placement and expired February 28, 2021 have been exercised for aggregate proceeds of $1,037,524.


› Read more
Recent Press Releases

XORTX Participating in WuXI Healthcare Forum

  • March 1, 2021
  • by aaronbb

● Advancing Partner and Investor Outreach Activities ●

CALGARY, Alberta, March 01, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces its participation in the WuXI Healthcare Forum to be held virtually March 15-18, 2021.


› Read more
Recent Press Releases

XORTX to Present at BIO CEO and Investor Conference

  • February 17, 2021
  • by aaronbb

● Strategies to Decrease Acute and Chronic Kidney Injury, Co-morbidity and Mortality ●

CALGARY, Alberta, Feb. 17, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that the Company is participating in the BIO CEO and Investor Digital Conference to be held virtually February 16-18, 2021.


› Read more
Recent Press Releases

XORTX Closes Over Subscribed Private Placement

  • February 10, 2021
  • by aaronbb

CALGARY, Alberta, Feb. 10, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that it has closed the over-subscribed private placement, initially announced on January 7, 2021, for total gross proceeds of $6.1 million (the “Offering”).


› Read more
Recent Press Releases

XORTX Announces Over Subscribed Private Placement

  • February 8, 2021
  • by aaronbb

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

CALGARY, Alberta, Feb. 08, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that further to its press release of January 28th, the Company is further increasing the private placement due to the high level of interest.


› Read more
Recent Press Releases

XORTX Announces Increase to Private Placement

  • January 28, 2021
  • by aaronbb

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATES

CALGARY, Alberta, Jan. 28, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that further to its press release of January 7th, the Company has received significant interest in the non-brokered private placement.


› Read more
Recent Press Releases

XORTX Provides Corporate Update

  • January 19, 2021
  • by aaronbb

● Synopsis of 2020 Achievements and Key Activities for 2021 ●

CALGARY, Alberta, Jan. 19, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to provide a synopsis of 2020 achievements and guidance on key activities for 2021.


› Read more
Recent Press Releases

XORTX Grants Options

  • January 12, 2021
  • by aaronbb

CALGARY, Alberta, Jan. 12, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has granted in accordance with the Company’s stock option plan an aggregate of 700,000 options to purchase common shares of the Company to a consultant and a director of the Company.


› Read more
Recent Press Releases

XORTX Announces Private Placement

  • January 7, 2021
  • by aaronbb

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATES

CALGARY, Alberta, Jan. 07, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces a non-brokered private placement to raise between CDN $2,000,000 and CDN $3,000,000 through the issuance of between 8,000,000 and 12,000,000 common share units of the Company at a price of CDN $0.25 per unit (the “Private Placement”).


› Read more

Posts navigation

1 2 3 … 7

Press Releases

  • XORTX Confirms $1 Million in Warrant Exercise Proceeds March 2, 2021
  • XORTX Confirms $1 Million in Warrant Exercise Proceeds March 2, 2021
  • XORTX Participating in WuXI Healthcare Forum March 1, 2021
  • XORTX to Present at BIO CEO and Investor Conference February 17, 2021
  • XORTX Closes Over Subscribed Private Placement February 10, 2021
XORTX Therapeutics Inc.
4000, 421 7th Avenue SW
Calgary, Alberta T2P 4K9
Ph: +1 (403) 455-7727
info@xortx.com
Theme by Colorlib Powered by WordPress